Bilateral NSF/BIO-BBSRC: Bayesian Quantitative Proteomics

Lead Research Organisation: University of Liverpool
Department Name: Institute of Integrative Biology

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Planned Impact

As well as the academic beneficiaries, the proposed research has significant prospective impact for the mass spectrometry industry and associated proteomics vendors. The proposed Bayesian Quantiative Proteomics platform will increase the amount of usable data extracted from LC-MS and therefore correspondingly increase users' return on investment. This will make commercial mass spectrometry instrumentation, which requires considerable capital and running costs, more attractive. In particular, we hope this extra research capacity will attract a wider uptake of mass spectrometry in environmental, biological and health research in industry and academia, as well as a wider audience of users and uses amongst systems biology researchers.

There is potential for direct impact through the licensing of some or all of our software tools developed, as we are working towards for other packages with Waters Inc.

There is considerable potential in this application for providing indirect benefits to UK public health, quality of life and environmental sustainability. Our aim is to establish a powerful platform for differential proteoform analysis and discovery enabling a wealth of new investigations in the biological sciences and translational medicine. Due to its success and further substantial promise, the BBSRC, UK research councils and industry have invested greatly in the systems biology approach. The potential improvements yielded by our workflow will therefore have a clear dissemination route to the public through reduced resources, costs and overheads required for discoveries realised with systems approaches in environmental, biological and biomedical science, and the characterisation of those discoveries.

The PDRAs employed on this grant benefit significantly from exposure to the wealth of proteome informatics expertise we will bring together, particularly since the PDRAs will be encouraged to play a significant role in public dissemination. All staff will benefit through being engaged within an international, cutting edge interdisciplinary project.
 
Description We are working on statistical approaches for proteomics, and developing new software for quantification. We have now understood better how to estimate false localisation rate on phospho-peptides, and determination of differential expression by Bayesian methods. The grant is still running but grants describing these developments are in preparation / under submission. The improved understanding of signal processing has also indirectly led to the development of our lcmsWorld software for high-performance 3D visualisation of LC-MS data.
Exploitation Route Software is being considered for commercialisation e.g. via Follow On funding.
Sectors Digital/Communication/Information Technologies (including Software),Healthcare,Pharmaceuticals and Medical Biotechnology

 
Description There is commercial interest from some MS vendors to take methods forward, and potentially commercialise. More to follow as this develops.
First Year Of Impact 2019